This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Krautz, G. M. Articles by Krettli, A. U. Search for Related Content PubMed PubMed Citation Articles by Krautz, G. M. Articles by Krettli, A. U. Pubmed/NCBI databases Medline Plus Health Information Chagas Disease

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, 08 1995, 2086-2090, Vol 33, No. 8
Copyright © 1995 by the American Society for Microbiology. All rights reserved.

Use of a 24-kilodalton Trypanosoma cruzi recombinant protein to monitor cure of human Chagas' disease

GM Krautz, LM Galvao, JR Cancado, A Guevara-Espinoza, A Ouaissi and AU Krettli
Department of Biochemistry and Immunology, Federal University of Minas Gerais, Belo Horizonte, Brazil.

A 24-kDa recombinant protein from Trypanosoma cruzi (rTc24) was evaluated by enzyme-linked immunosorbent assay (ELISA) and Western blot (immunoblot) tests to identify treated chagasic patients considered parasitologically cured on the basis of persistently negative tests of hemocultures and lytic antibodies. Some of these patients were termed dissociated because their sera, although negative by the complement- mediated lysis test, were positive by conventional serology. The negative lysis test indicates the absence of active infection after specific treatment, but this assay requires live and infectious parasites and cannot be used easily in a laboratory routine. Here we tested rTc24 by ELISA and Western blotting as an alternative for the complement-mediated lysis test. For the group of patients with active infection despite the treatment (uncured patients), all the sera tested recognized rTc24 in both tests. For the dissociated patients, approximately 80% of the sera did not react with rTc24 in the ELISA or in Western blots, in agreement with the negative complement-mediated lysis tests. Thus, the 24-kDa T. cruzi recombinant antigen, when used for initial trials to evaluate cure of chagasic patients submitted to specific treatment, will allow the identification of most, but not all, cases.

This article has been cited by other articles:

• Aguirre, S., Silber, A. M., Brito, M. E. F., Ribone, M. E., Lagier, C. M., Marcipar, I. S. (2006). Design, construction, and evaluation of a specific chimeric antigen to diagnose chagasic infection.. J. Clin. Microbiol. 44: 3768-3774 [Abstract] [Full Text]  
• FLORES-CHAVEZ, M., BOSSENO, M.-F., BASTRENTA, B., DALENZ, J.-L. A., HONTEBEYRIE, M., REVOLLO, S., BRENIERE, S. F. (2006). POLYMERASE CHAIN REACTION DETECTION AND SEROLOGIC FOLLOW-UP AFTER TREATMENT WITH BENZNIDAZOLE IN BOLIVIAN CHILDREN INFECTED WITH A NATURAL MIXTURE OF TRYPANOSOMA CRUZI I AND II.. Am J Trop Med Hyg 75: 497-501 [Abstract] [Full Text]  
• Meira, W. S. F., Galvao, L. M. C., Gontijo, E. D., Machado-Coelho, G. L. L., Norris, K. A., Chiari, E. (2004). Use of the Trypanosoma cruzi Recombinant Complement Regulatory Protein To Evaluate Therapeutic Efficacy following Treatment of Chronic Chagasic Patients. J. Clin. Microbiol. 42: 707-712 [Abstract] [Full Text]